BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 37353557)

  • 1. Rare subtypes of triple negative breast cancer: Current understanding and future directions.
    Thomas A; Reis-Filho JS; Geyer CE; Wen HY
    NPJ Breast Cancer; 2023 Jun; 9(1):55. PubMed ID: 37353557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease Behavior and Treatment Response of Special Histological Types of Triple-Negative Breast Cancer.
    Bonadio RC; Costa FA; Mendes SV; Araujo BJ; Nader-Marta G; Pinto PBC; Batista DN; Testa L; Ferrari MS
    Clin Breast Cancer; 2022 Dec; 22(8):e892-e900. PubMed ID: 36130851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Clinicopathological Features and Survival Outcomes of Different Histological Subtypes in Triple-negative Breast Cancer.
    Liao HY; Zhang WW; Sun JY; Li FY; He ZY; Wu SG
    J Cancer; 2018; 9(2):296-303. PubMed ID: 29344276
    [No Abstract]   [Full Text] [Related]  

  • 4. TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma.
    Yoon EC; Wang G; Parkinson B; Huo L; Peng Y; Wang J; Salisbury T; Wu Y; Chen H; Albarracin CT; Resetkova E; Middleton LP; Krishnamurthy S; Gan Q; Sun H; Huang X; Shen T; Chen W; Parwani AV; Sahin AA; Li Z; Ding Q
    Hum Pathol; 2022 Jul; 125():97-107. PubMed ID: 35413381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and Demographic Factors, Treatment Patterns, and Overall Survival Associated With Rare Triple-Negative Breast Carcinomas in the US.
    Elimimian EB; Samuel TA; Liang H; Elson L; Bilani N; Nahleh ZA
    JAMA Netw Open; 2021 Apr; 4(4):e214123. PubMed ID: 33844001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants.
    Pareja F; Geyer FC; Marchiò C; Burke KA; Weigelt B; Reis-Filho JS
    NPJ Breast Cancer; 2016; 2():16036. PubMed ID: 28721389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer: a systematic review.
    Trapani D; Giugliano F; Uliano J; Zia VAA; Marra A; Viale G; Ferraro E; Esposito A; Criscitiello C; D'amico P; Curigliano G
    Breast Cancer Res Treat; 2021 Jun; 187(2):323-337. PubMed ID: 34043122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple-Negative Breast Cancer Histological Subtypes with a Favourable Prognosis.
    Cserni G; Quinn CM; Foschini MP; Bianchi S; Callagy G; Chmielik E; Decker T; Fend F; Kovács A; van Diest PJ; Ellis IO; Rakha E; Tot T; European Working Group For Breast Screening Pathology
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
    Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
    BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis.
    Mills MN; Yang GQ; Oliver DE; Liveringhouse CL; Ahmed KA; Orman AG; Laronga C; Hoover SJ; Khakpour N; Costa RLB; Diaz R
    Eur J Cancer; 2018 Jul; 98():48-58. PubMed ID: 29870876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple-Negative Breast Cancer: Clinical and Histological Correlations.
    Elsawaf Z; Sinn HP
    Breast Care (Basel); 2011; 6(4):273-278. PubMed ID: 22135625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.
    Yam C; Mani SA; Moulder SL
    Oncologist; 2017 Sep; 22(9):1086-1093. PubMed ID: 28559413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics and prognosis of 17 special histologic subtypes of invasive breast cancers according to World Health Organization classification: comparative analysis to invasive carcinoma of no special type.
    Kim J; Kim JY; Lee HB; Lee YJ; Seong MK; Paik N; Park WC; Park S; Jung SP; Bae SY;
    Breast Cancer Res Treat; 2020 Nov; 184(2):527-542. PubMed ID: 32794061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of GHRH-R, a Potentially Targetable Biomarker, in Triple-negative Breast Cancer.
    Khanlari M; Schally AV; Block NL; Nadji M
    Appl Immunohistochem Mol Morphol; 2018 Jan; 26(1):1-5. PubMed ID: 29206714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial to mesenchymal transition and microRNA expression are associated with spindle and apocrine cell morphology in triple-negative breast cancer.
    Koleckova M; Ehrmann J; Bouchal J; Janikova M; Brisudova A; Srovnal J; Staffova K; Svoboda M; Slaby O; Radova L; Vomackova K; Melichar B; Veverkova L; Kolar Z
    Sci Rep; 2021 Mar; 11(1):5145. PubMed ID: 33664322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple negative breast cancer: looking for the missing link between biology and treatments.
    Palma G; Frasci G; Chirico A; Esposito E; Siani C; Saturnino C; Arra C; Ciliberto G; Giordano A; D'Aiuto M
    Oncotarget; 2015 Sep; 6(29):26560-74. PubMed ID: 26387133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers.
    Yoon EC; Wilson P; Zuo T; Pinto M; Cole K; Harigopal M
    Hum Pathol; 2020 Aug; 102():13-22. PubMed ID: 32565323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
    Lehmann BD; Jovanović B; Chen X; Estrada MV; Johnson KN; Shyr Y; Moses HL; Sanders ME; Pietenpol JA
    PLoS One; 2016; 11(6):e0157368. PubMed ID: 27310713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
    Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
    Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
    Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
    Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.